O
OMass Therapeutics
A drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets
About OMass Therapeutics
OMass Therapeutics is a private biotechnology company focused on the discovery and development of small molecule drugs against inadequately drugged or intractable targets.
The company's proprietary drug discovery platform, OdyssION, integrates novel biochemistry techniques, native mass spectrometry, and custom chemistry to study how a protein interacts with its native ecosystem. This approach allows for the identification of drug candidates that can modulate the activity of these targets.
OMass is building a pipeline of small molecule therapeutics in the areas of rare diseases and immunology. The company's pipeline targets solute carriers, complex-bound proteins, and G protein-coupled receptors (GPCRs).
The company's business model is to leverage its platform to develop a portfolio of drug candidates and then to partner with larger pharmaceutical companies for later-stage development and commercialization. OMass has raised significant capital to advance its pipeline, including a $100 million Series B financing.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 77
- Open positions
- 1
- Dealroom signal
- 68.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Disease, Genome Engineering, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2023 | $13M | $498M | British Patient Capital | ↗ |
| SERIES BOther financing | Apr 2022 | $100M | $399M | Syncona · Northpond Ventures · University of Oxford · Oxford Science Enterprises | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OMass Therapeutics is 5.5K monthly website visits, up 19.6% over the last three months. OMass Therapeutics's team declined 4.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Oxford Science Enterprises
Series A6 investors entered at this stage
Syncona
Northpond Ventures
GV
Sanofi Ventures
University of Oxford
British Patient Capital
Other known investors1 additional known investor
Oxford University Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OMass Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OMass Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.